Nantahala Capital Management Increases Stake in Abeona Therapeutics (ABEO) to 9.99%

Nantahala Capital Management, LLC, along with its principals Wilmot B. Harkey and Daniel Mack, filed a Schedule 13G/A on May 15, 2026, reporting a significant increase in their position in Abeona Therapeutics Inc. (ABEO). As of March 31, 2026, the reporting persons collectively beneficially own 5,775,350 shares of common stock, representing a 9.99% ownership stake in the company. This is a substantial increase from a previously reported 0.0% position. The total share count includes 762,298 shares that may be acquired within 60 days through the exercise of convertible securities. Nantahala Capital Partners Limited Partnership is identified as a fund that has the right to receive dividends or proceeds from more than 5% of the outstanding shares. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The reporting persons share voting and dispositive power over all reported shares.